Gassert, Felix G.
Joseph, Gabby B.
Lynch, John A.
Luitjens, Johanna
Nevitt, Michael C.
McCulloch, Charles E.
Lane, Nancy E.
Majumdar, Sharmila
Link, Thomas M.
Funding for this research was provided by:
National Institutes of Health (NIH R01-AR064771, NIH R01-AR078917, R01-AG070647, N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262, NIH R01-AR064771, NIH R01-AR078917, R01-AG070647, N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262)
Merck
Novartis Pharmaceuticals Corporation
Pfizer
North Carolina GlaxoSmithKline Foundation
Article History
Received: 9 January 2024
Accepted: 12 June 2024
First Online: 26 June 2024
Declarations
:
: Not applicable. Consent to participate is covered by the Osteoarthritis Initiative. The analyses in this study are based on data from the Osteoarthritis Initiative (OAI, ). Institutional review boards of each center approved informed consent documentation, study protocols and amendments. All investigations were carried out in compliance with the Helsinki Declaration.
: Not applicable.
: The authors declare no competing interests.